https://www.sironabiochem.com/wp-content/uploads/2020/11/SBM-Investor-Presentation-November2020.pdf
They checked off the "Publish in a reputable journal" box.
Which leaves the following heavy lifting for Howard and crew to complete:
•Finalize the Beijing Huaxi Pharma Co, Ltd. collaboration agreement
•Complete an additional licensing agreement for the SGLT2 inhibitor in new markets
•Secure non dilutive funding through anticipated collaborations
•Finalize Tinyi agreement
•Complete a clinical trial for an increased dose of TFC 1067 (.4 %)
•Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II
•Complete safety studies and enter clinical trial for anti wrinkle compound
•Develop new anti viral compounds and advance them into preclinical studies